You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethadone
Accession NumberDB00333  (APRD00485)
TypeSmall Molecule
GroupsApproved
DescriptionA synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). In Australia methadone is a Schedule 8 (controlled) drug.
Structure
Thumb
Synonyms
(+-)-Methadone
(+/-)-Methadone
(±)-methadone
6-Dimethylamino-4,4-diphenyl-3-heptanone
dl-Methadone
Methadonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DisketsTablet40 mg/1OralWest Ward Pharmaceuticals Corp.1973-03-14Not applicableUs
DolophineTablet5 mg/1OralWest Ward Pharmaceuticals Corp.1947-08-13Not applicableUs
DolophineTablet10 mg/1OralWest Ward Pharmaceuticals Corp.1947-08-13Not applicableUs
Dolophine HydrochlorideTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Dolophine HydrochlorideTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
MetadolTablet25 mgOralPaladin Labs Inc2003-07-29Not applicableCanada
MetadolSolution1 mgOralPaladin Labs Inc2003-07-11Not applicableCanada
MetadolLiquid10 mgOralPaladin Labs Inc2000-05-05Not applicableCanada
MetadolTablet1 mgOralPaladin Labs Inc2003-07-29Not applicableCanada
MetadolTablet5 mgOralPaladin Labs Inc2003-07-29Not applicableCanada
MetadolTablet10 mgOralPaladin Labs Inc2003-07-29Not applicableCanada
Metadol-DTablet5 mgOralPaladin Labs IncNot applicableNot applicableCanada
Metadol-DTablet10 mgOralPaladin Labs IncNot applicableNot applicableCanada
Metadol-DLiquid10 mgOralPaladin Labs Inc2001-08-03Not applicableCanada
Metadol-DTablet25 mgOralPaladin Labs IncNot applicableNot applicableCanada
Metadol-DSolution1 mgOralPaladin Labs Inc2014-08-18Not applicableCanada
Metadol-DTablet1 mgOralPaladin Labs IncNot applicableNot applicableCanada
Methadone HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC1947-08-13Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralWest Ward Pharmaceuticals Corp.1947-08-13Not applicableUs
Methadone HydrochloridePowder1 g/gOralMallinckrodt, Inc.2012-04-30Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralWest Ward Pharmaceuticals Corp.1947-08-13Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC1947-08-13Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralDIRECT RX2014-01-01Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralWest Ward Pharmaceuticals Corp.1947-08-13Not applicableUs
Methadone HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousMylan Institutional LLC1947-08-13Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralSTAT Rx USA LLC1947-08-13Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralWest Ward Pharmaceuticals Corp.1947-08-13Not applicableUs
MethadoseConcentrate10 mg/mLOralMallinckrodt, Inc.2010-03-10Not applicableUs
MethadoseConcentrate10 mg/mLOralAtlantic Biologicals Corps2010-03-10Not applicableUs
MethadoseSolution10 mgOralMallinckrodt Canada Ulc2013-01-03Not applicableCanada
MethadoseConcentrate10 mg/mLOralUnit Dose Services2010-03-10Not applicableUs
MethadoseSolution10 mgOralMallinckrodt Canada Ulc2013-01-03Not applicableCanada
Methadose Sugar-freeConcentrate10 mg/mLOralMallinckrodt, Inc.2010-03-10Not applicableUs
PMS-methadoneTablet1 mgOralPaladin Labs IncNot applicableNot applicableCanada
PMS-methadoneTablet5 mgOralPaladin Labs IncNot applicableNot applicableCanada
PMS-methadoneTablet10 mgOralPaladin Labs IncNot applicableNot applicableCanada
PMS-methadoneTablet25 mgOralPaladin Labs IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methadone HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-11Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralAscend Laboratories, LLC2012-01-16Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-01-16Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralMajor Pharmaceuticals2012-01-16Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralPhysicians Total Care, Inc.2004-01-07Not applicableUs
Methadone HydrochlorideConcentrate10 mg/mLOralWest Ward Pharmaceuticals Corp.1988-09-06Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralAurolife Pharma, LLC2015-09-15Not applicableUs
Methadone HydrochlorideSolution10 mg/5mLOralVista Pharm Inc2010-08-01Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralMallinckrodt, Inc.2009-05-19Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-09-15Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralAmerican Health Packaging2014-10-02Not applicableUs
Methadone HydrochlorideTablet40 mg/1OralMallinckrodt, Inc.2010-08-31Not applicableUs
Methadone HydrochlorideConcentrate10 mg/mLOralVista Pharm Inc2009-10-30Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralPhysicians Total Care, Inc.2007-03-12Not applicableUs
Methadone HydrochlorideSolution5 mg/5mLOralWest Ward Pharmaceuticals Corp.1981-05-22Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralSTAT Rx USA LLC2009-05-19Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralVista Pharm, Inc.1998-05-29Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralAmerican Health Packaging2016-12-01Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralH.J. Harkins Company Inc.2009-05-19Not applicableUs
Methadone HydrochlorideConcentrate10 mg/mLOralRoxane Laboratories, Inc1988-04-30Not applicableUs
Methadone HydrochlorideConcentrate10 mg/mLOralVista Pharm Inc2011-12-01Not applicableUs
Methadone HydrochlorideTablet40 mg/1OralAmerican Health Packaging2015-03-312017-05-31Us
Methadone HydrochlorideTablet10 mg/1Oralbryant ranch prepack2009-05-19Not applicableUs
Methadone HydrochlorideSolution10 mg/5mLOralWest Ward Pharmaceuticals Corp.1982-08-30Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralSTAT Rx USA LLC2009-05-19Not applicableUs
Methadone HydrochlorideTablet40 mg/1OralVista Pharm, Inc.1998-03-25Not applicableUs
Methadone HydrochlorideConcentrate10 mg/mLOralRoxane Laboratories, Inc1988-04-30Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralH.J. Harkins Company Inc.2009-05-19Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralAurolife Pharma, LLC2015-09-15Not applicableUs
Methadone HydrochlorideSolution5 mg/5mLOralVista Pharm Inc2010-08-01Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralMallinckrodt, Inc.2009-05-19Not applicableUs
Methadone HydrochlorideTablet5 mg/1Oralbryant ranch prepack2009-05-19Not applicableUs
Methadone HydrochlorideSolution5 mg/5mLOralAtlantic Biologicals Corps1981-05-22Not applicableUs
MethadoseTablet5 mg/1OralMallinckrodt, Inc.2010-02-23Not applicableUs
Methadose DispersibleTablet40 mg/1OralMallinckrodt, Inc.2010-08-31Not applicableUs
Methadose DispersibleTablet40 mg/1OralAmerican Health Packaging2016-06-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdolanNot Available
DepridolNot Available
HeptadonNot Available
HeptanonNot Available
KetalginNot Available
MephenonNot Available
PhyseptoneNot Available
PolamidonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methadone Hydrochloride
1095-90-5
Thumb
  • InChI Key: FJQXCDYVZAHXNS-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.18594223
  • Average Mass: 345.906
DBSALT000346
Categories
UNIIUC6VBE7V1Z
CAS number76-99-3
WeightAverage: 309.4452
Monoisotopic: 309.209264491
Chemical FormulaC21H27NO
InChI KeyUSSIQXCVUWKGNF-UHFFFAOYSA-N
InChI
InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
IUPAC Name
6-(dimethylamino)-4,4-diphenylheptan-3-one
SMILES
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of dry cough, drug withdrawal syndrome, opioid type drug dependence, and pain.
Structured Indications
PharmacodynamicsMethadone is a synthetic opioid analgesic with multiple actions quantitatively similar to those at morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, Methadone is more active and more toxic than morphine. Methadone is indicated for relief of severe pain, for detoxification treatment of narcotic addiction, and for temporary maintenance treatment of narcotic addiction. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The Methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.
Mechanism of actionMethadone is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The principal therapeutic uses for methadone are for analgesia and for detoxification or maintenance in opioid addiction. The methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown. Other NMDA receptor antagonists have been shown to produce neurotoxic effects in animals.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Glutamate receptor ionotropic, NMDA 3AProteinyes
antagonist
HumanQ8TCU5 details
Neuronal acetylcholine receptor subunit alpha-10Proteinyes
antagonist
HumanQ9GZZ6 details
Delta-type opioid receptorProteinyes
agonist
HumanP41143 details
5-hydroxytryptamine receptor 3AProteinunknown
antagonist
HumanP46098 details
Related Articles
AbsorptionWell absorbed following oral administration. The bioavailability of methadone ranges between 36 to 100%.
Volume of distribution
  • 1.0 to 8.0 L/kg
Protein bindingIn plasma, methadone is predominantly bound to α1-acid glycoprotein (85% to 90%).
Metabolism

Hepatic. Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine.

SubstrateEnzymesProduct
Methadone
2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)Details
2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)
2-Ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP)Details
Route of eliminationThe elimination of methadone is mediated by extensive biotransformation, followed by renal and fecal excretion. Unmetabolized methadone and its metabolites are excreted in urine to a variable degree.
Half life24-36 hours
Clearance
  • 1.4 to 126 L/h
ToxicityIn severe overdosage, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Methadone Metabolism PathwayDrug metabolismSMP00624
Methadone Action PathwayDrug actionSMP00408
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Methadone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Methadone.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Methadone.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Methadone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Methadone.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Methadone.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methadone is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Methadone.Experimental
AbacavirThe therapeutic efficacy of Abacavir can be decreased when used in combination with Methadone.Approved, Investigational
AbirateroneThe serum concentration of Methadone can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Methadone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Methadone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Methadone is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Methadone.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Methadone is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Methadone is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Methadone.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Methadone.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Methadone.Approved
adipiplonThe risk or severity of adverse effects can be increased when Methadone is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Methadone.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Methadone is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Methadone.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Methadone.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Methadone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Methadone.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Methadone.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Methadone.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Methadone is combined with Almotriptan.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Methadone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methadone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Methadone.Approved, Withdrawn
AlvimopanThe risk or severity of adverse effects can be increased when Methadone is combined with Alvimopan.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Methadone.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Methadone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Methadone is combined with Amiloride.Approved
AminoglutethimideThe serum concentration of Methadone can be increased when it is combined with Aminoglutethimide.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Methadone.Approved, Withdrawn
AmiodaroneMethadone may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Methadone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methadone.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Methadone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Methadone is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Methadone.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Methadone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Methadone.Approved
AnagrelideMethadone may increase the QTc-prolonging activities of Anagrelide.Approved
AnastrozoleThe serum concentration of Methadone can be increased when it is combined with Anastrozole.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Methadone.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Methadone.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Methadone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Methadone.Approved, Investigational
AprepitantThe serum concentration of Methadone can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Methadone.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Methadone.Approved, Investigational
AripiprazoleMethadone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Methadone can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideMethadone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMethadone may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Methadone is combined with Articaine.Approved
AsenapineMethadone may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Methadone.Approved, Withdrawn
AtazanavirThe metabolism of Methadone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Methadone.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Methadone.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methadone.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Methadone.Approved, Vet Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Methadone.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Methadone is combined with Azaperone.Vet Approved
AzelastineMethadone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Methadone.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Methadone.Approved
AzosemideThe risk or severity of adverse effects can be increased when Methadone is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Methadone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Barbital.Illicit
BedaquilineMethadone may increase the QTc-prolonging activities of Bedaquiline.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Methadone.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Methadone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Methadone is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Methadone.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Methadone.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Methadone.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Methadone.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Methadone.Approved, Vet Approved
BetaxololThe metabolism of Methadone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Methadone can be decreased when it is combined with Bexarotene.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Methadone is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Methadone.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Methadone.Approved
BL-1020BL-1020 may increase the hypotensive activities of Methadone.Investigational
BoceprevirThe serum concentration of Methadone can be increased when it is combined with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Methadone.Approved, Investigational
BosentanThe serum concentration of Methadone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Methadone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Methadone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Methadone.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Methadone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Methadone is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Methadone is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Methadone.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Methadone is combined with Brotizolam.Approved, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Methadone.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Methadone is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Methadone.Approved, Investigational
BuprenorphineMethadone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Methadone can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Methadone.Approved
BuspironeThe risk or severity of adverse effects can be increased when Methadone is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methadone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Methadone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Methadone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Methadone is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Methadone.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Methadone.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methadone.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Methadone.Approved
CamazepamCamazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Methadone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Methadone.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Methadone is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Methadone is combined with Canrenone.Investigational
CapecitabineThe metabolism of Methadone can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Methadone.Approved
CarbamazepineThe metabolism of Methadone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Methadone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Methadone.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Methadone.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Methadone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Methadone.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Methadone.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Methadone.Approved, Investigational
CelecoxibThe metabolism of Methadone can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Methadone.Approved, Vet Approved
CeritinibThe serum concentration of Methadone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Methadone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Methadone is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Methadone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Methadone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Methadone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Chloroprocaine.Approved
ChloroquineMethadone may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Methadone.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Methadone.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Methadone.Illicit, Withdrawn
ChlorpromazineMethadone may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Methadone.Approved
CholecalciferolThe metabolism of Methadone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Methadone is combined with Cicletanine.Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Methadone.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Methadone.Approved
CinacalcetThe metabolism of Methadone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Methadone.Approved
CiprofloxacinMethadone may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMethadone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Methadone.Approved
CitalopramThe metabolism of Methadone can be decreased when combined with Citalopram.Approved
ClarithromycinMethadone may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Methadone can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Methadone.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Methadone is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Methadone.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Methadone is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Methadone.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Methadone is combined with Clomipramine.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Methadone.Approved
ClopidogrelThe metabolism of Methadone can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
ClotrimazoleThe metabolism of Methadone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineMethadone may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Methadone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Methadone.Approved
CocaineThe metabolism of Methadone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Methadone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Methadone.Approved
ConivaptanThe serum concentration of Methadone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Methadone.Approved
CrizotinibMethadone may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Methadone is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Methadone.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Methadone.Approved, Investigational
CyclosporineThe metabolism of Methadone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Methadone is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Methadone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Methadone.Approved
DabrafenibThe serum concentration of Methadone can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Methadone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Methadone is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Methadone.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methadone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Methadone.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Methadone.Approved, Investigational
DarunavirThe serum concentration of Methadone can be decreased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Methadone.Approved
DasatinibThe serum concentration of Methadone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Methadone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Methadone.Approved
DeferasiroxThe serum concentration of Methadone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Methadone.Approved
DelavirdineThe metabolism of Methadone can be increased when combined with Delavirdine.Approved
DelorazepamDelorazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
deramciclaneThe risk or severity of adverse effects can be increased when Methadone is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Methadone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Methadone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Methadone is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.Approved
DesvenlafaxineThe metabolism of Methadone can be decreased when combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Methadone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Methadone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methadone is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Methadone.Withdrawn
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Methadone.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Methadone is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Methadone.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Methadone.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Methadone is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Methadone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methadone is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Methadone is combined with Dezocine.Approved
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadone.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Methadone.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Methadone.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Methadone.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Methadone is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Methadone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Methadone.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Methadone.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methadone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Methadone.Illicit
DiltiazemThe metabolism of Methadone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Methadone is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Methadone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Methadone is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Methadone.Approved
DisopyramideMethadone may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Methadone.Approved, Investigational
DofetilideMethadone may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronMethadone may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneMethadone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Methadone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Methadone.Approved
DoramectinThe risk or severity of adverse effects can be increased when Methadone is combined with Doramectin.Vet Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Methadone.Approved
DoxepinThe risk or severity of adverse effects can be increased when Methadone is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Methadone.Approved, Investigational
DoxycyclineThe metabolism of Methadone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Methadone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
DronedaroneMethadone may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Methadone is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Methadone is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Methadone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Methadone is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Methadone is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Methadone is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Methadone.Approved
EfavirenzThe metabolism of Methadone can be increased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Methadone is combined with Efonidipine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Methadone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Methadone.Approved
EluxadolineMethadone may increase the constipating activities of Eluxadoline.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Methadone.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Methadone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methadone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Methadone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Methadone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Methadone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Methadone is combined with Eplerenone.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Methadone is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Methadone is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Methadone is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Methadone.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Methadone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Methadone.Approved, Vet Approved
EscitalopramThe metabolism of Methadone can be decreased when combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Methadone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Methadone.Investigational
EsomeprazoleThe metabolism of Methadone can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Methadone.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Methadone.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Methadone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Methadone is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Methadone is combined with Etacrynic acid.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methadone.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Methadone.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Methadone.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Methadone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Methadone is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Methadone is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methadone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methadone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Methadone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Methadone is combined with Etifoxine.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methadone.Approved
EtoperidoneThe metabolism of Methadone can be decreased when combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Methadone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Methadone.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Methadone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Methadone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Methadone.Approved
ExemestaneThe serum concentration of Methadone can be increased when it is combined with Exemestane.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Methadone.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Methadone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Methadone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Methadone.Approved
FelodipineThe metabolism of Methadone can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Methadone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Methadone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methadone.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Methadone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Methadone.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Methadone.Approved, Investigational
FlecainideMethadone may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Methadone is combined with Flibanserin.Approved
FloxuridineThe metabolism of Methadone can be decreased when combined with Floxuridine.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Methadone.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
FlumazenilFlumazenil may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Methadone.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
FluorouracilThe metabolism of Methadone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Methadone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolMethadone may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Methadone.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Methadone.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methadone is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Methadone.Approved
FluvoxamineThe metabolism of Methadone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Methadone can be increased when it is combined with Formestane.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Methadone.Approved, Investigational
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Methadone resulting in a loss in efficacy.Approved
FosaprepitantThe serum concentration of Methadone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Methadone.Approved
FosphenytoinThe serum concentration of Methadone can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Methadone is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Methadone is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Methadone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Methadone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Methadone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Methadone is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methadone is combined with gabapentin enacarbil.Approved
Gadobenic acidMethadone may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Methadone.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Methadone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Methadone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Methadone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Methadone.Approved
GemfibrozilThe metabolism of Methadone can be decreased when combined with Gemfibrozil.Approved
GemifloxacinMethadone may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Methadone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Methadone is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Methadone.Approved, Investigational, Vet Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Methadone.Approved
GranisetronMethadone may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Methadone.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Methadone.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Methadone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Methadone.Approved
HaloperidolMethadone may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Methadone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Methadone is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Methadone.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Methadone.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Methadone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Methadone.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Methadone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Methadone.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Methadone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methadone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Methadone.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Methadone.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Methadone.Approved
IbutilideMethadone may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Methadone.Approved
IdelalisibThe serum concentration of Methadone can be increased when it is combined with Idelalisib.Approved
IloperidoneMethadone may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Methadone can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Methadone is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Methadone.Approved
IndalpineThe metabolism of Methadone can be decreased when combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Methadone is combined with Indapamide.Approved
IndinavirThe metabolism of Methadone can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Methadone.Approved, Investigational
Interferon Alfa-2a, RecombinantThe serum concentration of Methadone can be increased when it is combined with Interferon Alfa-2a, Recombinant.Approved
Interferon Alfa-2b, RecombinantThe serum concentration of Methadone can be increased when it is combined with Interferon Alfa-2b, Recombinant.Approved
Interferon alfa-n3The serum concentration of Methadone can be increased when it is combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The serum concentration of Methadone can be increased when it is combined with Interferon alfacon-1.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Methadone.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Methadone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Methadone.Withdrawn
IrbesartanThe metabolism of Methadone can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Methadone.Approved, Investigational
IsavuconazoniumThe metabolism of Methadone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methadone.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Methadone.Approved, Vet Approved
IsoniazidThe metabolism of Methadone can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Methadone is combined with Isosorbide.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Methadone.Approved
ItraconazoleThe serum concentration of Methadone can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Methadone.Approved
IvacaftorThe serum concentration of Methadone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Methadone.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Methadone.Approved
KetamineThe risk or severity of adverse effects can be increased when Methadone is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Methadone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Methadone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Methadone can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Methadone is combined with KW-3902.Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Methadone.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Methadone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Methadone.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Methadone.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Methadone.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Methadone.Approved
LeflunomideThe metabolism of Methadone can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Methadone.Approved
LenvatinibMethadone may increase the QTc-prolonging activities of Lenvatinib.Approved
LetrozoleThe serum concentration of Methadone can be increased when it is combined with Letrozole.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Methadone.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Methadone.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Methadone is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Methadone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Methadone is combined with Levocetirizine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Methadone.Approved
LevofloxacinMethadone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methadone is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe metabolism of Methadone can be decreased when combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Methadone is combined with Levorphanol.Approved
LidocaineThe metabolism of Methadone can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Methadone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Methadone is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Methadone.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Methadone.Approved
LithiumThe risk or severity of adverse effects can be increased when Methadone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Lofentanil.Illicit
LomustineThe metabolism of Lomustine can be decreased when combined with Methadone.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Methadone.Approved
LopinavirMethadone may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Methadone.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Methadone is combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Methadone.Approved
LovastatinThe metabolism of Methadone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Methadone is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Methadone is combined with Lu AA21004.Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Methadone.Approved, Investigational
LuliconazoleThe serum concentration of Methadone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Methadone can be increased when it is combined with Lumacaftor.Approved
LumefantrineMethadone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Methadone is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Methadone is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Methadone.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadone.Approved
MeclizineThe risk or severity of adverse effects can be increased when Methadone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Methadone is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Methadone.Approved
MelatoninThe risk or severity of adverse effects can be increased when Methadone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Methadone is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Methadone.Investigational
MephentermineMephentermine may increase the analgesic activities of Methadone.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Methadone.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Methadone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Methadone is combined with Meprobamate.Approved, Illicit
MequitazineMethadone may increase the arrhythmogenic activities of Mequitazine.Approved
MersalylThe risk or severity of adverse effects can be increased when Methadone is combined with Mersalyl.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Methadone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Methadone is combined with Metaxalone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Methadone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Methadone.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Methadone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methadone is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methadone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methadone is combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Methadone.Approved
MethotrimeprazineMethadone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Methadone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Methadone.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Methadone.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Methadone.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Methadone.Approved, Illicit, Withdrawn
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Methadone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Methadone is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Methadone.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Methadone.Approved
MetyrosineMethadone may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Methadone can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Methadone.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Methadone.Approved, Investigational
MilnacipranThe metabolism of Methadone can be decreased when combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Methadone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Methadone.Approved
MirtazapineMethadone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Methadone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Methadone.Approved, Investigational
MMDAMMDA may increase the analgesic activities of Methadone.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methadone.Approved
ModafinilThe serum concentration of Methadone can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Methadone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Methadone is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Methadone.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be increased when it is combined with Methadone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Methadone.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Methadone.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Methadone.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Methadone.Approved
NafcillinThe serum concentration of Methadone can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Methadone.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Methadone.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Methadone.Approved, Vet Approved
NaltrexoneThe therapeutic efficacy of Methadone can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Methadone is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Methadone.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Methadone.Approved, Investigational
NefazodoneThe metabolism of Methadone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Methadone can be decreased when it is combined with Nelfinavir.Approved
NetazepideNetazepide may increase the central nervous system depressant (CNS depressant) activities of Methadone.Investigational
NetupitantThe serum concentration of Methadone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Methadone can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Methadone.Withdrawn
NicardipineThe metabolism of Methadone can be decreased when combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Methadone.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Methadone.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Methadone.Approved
NilotinibMethadone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Methadone.Approved
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Methadone.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Methadone is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Methadone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Methadone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Methadone is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Methadone.Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Methadone.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Methadone.Approved, Investigational
OfloxacinMethadone may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Methadone.Approved, Investigational
OlaparibThe metabolism of Methadone can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Methadone.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Methadone is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Methadone.Approved
OmeprazoleThe metabolism of Methadone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronMethadone may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Methadone is combined with Opium.Approved, Illicit
OrphenadrineMethadone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Methadone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Methadone can be increased when it is combined with Osimertinib.Approved
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Methadone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Methadone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadone.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Methadone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Methadone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Methadone.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Methadone.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Methadone.Approved, Vet Approved
PalbociclibThe serum concentration of Methadone can be increased when it is combined with Palbociclib.Approved
PaliperidoneMethadone may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Methadone.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Methadone.Approved
PanobinostatThe serum concentration of Methadone can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Methadone can be decreased when combined with Pantoprazole.Approved
ParaldehydeMethadone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Methadone.Approved
ParoxetineThe metabolism of Methadone can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Methadone.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Methadone.Approved
Peginterferon alfa-2aThe serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.Approved
PentamidineMethadone may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocinePentazocine may decrease the analgesic activities of Methadone.Approved, Vet Approved
PentobarbitalThe metabolism of Methadone can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Methadone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
PerazineThe risk or severity of adverse effects can be increased when Methadone is combined with Perazine.Investigational
PerflutrenMethadone may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Methadone.Approved
PerospironeThe risk or severity of adverse effects can be increased when Methadone is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Methadone.Approved
PethidineThe risk or severity of adverse effects can be increased when Methadone is combined with Pethidine.Approved
Pf 00477736Pf 00477736 may increase the central nervous system depressant (CNS depressant) activities of Methadone.Investigational
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Methadone.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methadone.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Methadone.Approved, Withdrawn
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Methadone.Withdrawn
PhenobarbitalThe serum concentration of Methadone can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methadone is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Methadone.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Methadone.Approved, Illicit
PhenytoinThe serum concentration of Methadone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideMethadone may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Methadone.Approved
PioglitazoneThe metabolism of Methadone can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Methadone.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Methadone.Approved
PirenzepinePirenzepine may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
PiretanideThe risk or severity of adverse effects can be increased when Methadone is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Methadone is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Methadone.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Methadone.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Methadone.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Methadone is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Methadone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Methadone.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Methadone.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleMethadone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Methadone.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Methadone.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Methadone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Methadone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methadone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Methadone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Prilocaine.Approved
PrimaquineMethadone may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Methadone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideMethadone may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Methadone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Methadone is combined with Procarbazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Methadone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methadone.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Methadone.Approved, Vet Approved
PromazineMethadone may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Methadone is combined with Promethazine.Approved
PropafenoneThe serum concentration of Methadone can be increased when it is combined with Propafenone.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Methadone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Methadone is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Methadone is combined with Propericiazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Methadone.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Methadone.Investigational
PropofolPropofol may increase the QTc-prolonging activities of Methadone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Methadone is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Methadone.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Methadone is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Methadone is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Methadone.Approved
PSD502The risk or severity of adverse effects can be increased when Methadone is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Methadone.Approved
PyrimethamineThe metabolism of Methadone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Methadone can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineMethadone may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Methadone is combined with Quinethazone.Approved
QuinidineMethadone may increase the QTc-prolonging activities of Quinidine.Approved
QuinineMethadone may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Methadone can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Methadone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Methadone is combined with Ramelteon.Approved, Investigational
RamosetronMethadone may increase the constipating activities of Ramosetron.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Methadone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Methadone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methadone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Methadone.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Methadone.Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Methadone.Approved
RifabutinThe serum concentration of Methadone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Methadone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Methadone can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Methadone.Approved, Investigational
RilpivirineThe metabolism of Methadone can be increased when combined with Rilpivirine.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Methadone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methadone is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Methadone.Investigational
RitonavirThe serum concentration of Methadone can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Methadone.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Methadone is combined with Rizatriptan.Approved
RolapitantThe metabolism of Methadone can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Methadone is combined with Rolofylline.Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Methadone.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Methadone is combined with Romifidine.Vet Approved
RopiniroleMethadone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Methadone.Approved
RosiglitazoneThe metabolism of Methadone can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineMethadone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methadone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Methadone is combined with S-Ethylisothiourea.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Methadone.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Methadone is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Methadone.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Methadone.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Methadone.Approved
SaquinavirMethadone may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Methadone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Methadone is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Methadone.Approved
SecobarbitalThe metabolism of Methadone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methadone.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Methadone.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Methadone.Approved, Withdrawn
SertralineThe metabolism of Methadone can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Methadone.Approved, Vet Approved
SildenafilThe metabolism of Methadone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Methadone.Approved
SiltuximabThe serum concentration of Methadone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Methadone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Methadone.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Methadone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Methadone.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Methadone.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Methadone.Approved, Investigational
SotalolMethadone may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Methadone.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Methadone.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Methadone.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Methadone is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Methadone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Methadone can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Methadone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Methadone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Methadone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Methadone.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Methadone is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Methadone is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Methadone.Approved, Investigational
SuvorexantMethadone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Methadone.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Methadone resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Methadone.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Methadone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methadone is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Methadone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Methadone.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Methadone.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Methadone.Investigational, Withdrawn
TelaprevirThe serum concentration of Methadone can be decreased when it is combined with Telaprevir.Approved
TelavancinMethadone may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMethadone may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Methadone.Approved
TenofovirThe metabolism of Methadone can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Methadone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Methadone.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Methadone.Withdrawn
TeriflunomideThe serum concentration of Methadone can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Methadone.Investigational
TetrabenazineMethadone may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Methadone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Methadone is combined with Tetrodotoxin.Investigational
ThalidomideMethadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Methadone is combined with Theobromine.Approved
TheophyllineThe metabolism of Methadone can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Methadone is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Methadone.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Methadone is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Methadone is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Methadone.Approved
ThiotepaThe metabolism of Methadone can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Methadone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Methadone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Methadone is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Methadone.Approved
TiclopidineThe metabolism of Methadone can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Methadone is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Methadone is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Methadone.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Methadone.Approved
TipranavirThe serum concentration of Methadone can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Methadone.Approved
TocilizumabThe serum concentration of Methadone can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Methadone can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Methadone is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Methadone.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Methadone.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Methadone is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Methadone is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Methadone.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Methadone is combined with Torasemide.Approved
ToremifeneMethadone may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Methadone.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Methadone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methadone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methadone.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Methadone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Methadone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Methadone is combined with Triamterene.Approved
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Methadone is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Methadone is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Methadone.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Methadone.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Methadone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Methadone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Methadone is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Methadone.Approved, Vet Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Methadone.Approved
TropisetronTropisetron may increase the serotonergic activities of Methadone.Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Methadone.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Methadone.Approved
Uc1010The risk or severity of adverse effects can be increased when Methadone is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Methadone is combined with Ularitide.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Methadone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Methadone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methadone.Approved, Investigational
ValsartanThe metabolism of Methadone can be decreased when combined with Valsartan.Approved, Investigational
VandetanibMethadone may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Methadone.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Methadone.Approved
VemurafenibThe serum concentration of Methadone can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Methadone.Approved
VenlafaxineThe metabolism of Methadone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Methadone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Methadone is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Methadone.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Methadone is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Methadone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Methadone.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Methadone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Methadone.Approved
VoriconazoleThe serum concentration of Methadone can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Methadone.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Methadone is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Methadone is combined with Xylazine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Methadone.Approved, Vet Approved
ZafirlukastThe metabolism of Methadone can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Methadone.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Methadone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methadone is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Methadone.Approved
ZimelidineThe metabolism of Methadone can be decreased when combined with Zimelidine.Withdrawn
ZiprasidoneMethadone may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Methadone.Approved, Investigational
ZolpidemMethadone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Methadone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Methadone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Methadone is combined with Zotepine.Approved
ZuclopenthixolMethadone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol. Usually diluted in fruit juice.
References
Synthesis Reference

Charles J. Barnett, “Modification of methadone synthesis process step.” U.S. Patent US4048211, issued August, 1952.

US4048211
General References
  1. Kell MJ: Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. J Addict Dis. 1994;13(1):5-26. [PubMed:8018740 ]
  2. Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. [PubMed:12405865 ]
  3. Joseph H, Stancliff S, Langrod J: Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000 Oct-Nov;67(5-6):347-64. [PubMed:11064485 ]
  4. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. [PubMed:17313907 ]
  5. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL: Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005 Oct;100(10):1496-509. [PubMed:16185211 ]
External Links
ATC CodesN07BC02N02AC52
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (327 KB)
MSDSDownload (60 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9772
Caco-2 permeable+0.7841
P-glycoprotein substrateSubstrate0.6224
P-glycoprotein inhibitor IInhibitor0.7627
P-glycoprotein inhibitor IINon-inhibitor0.9101
Renal organic cation transporterNon-inhibitor0.5851
CYP450 2C9 substrateNon-substrate0.7822
CYP450 2D6 substrateNon-substrate0.7743
CYP450 3A4 substrateSubstrate0.66
CYP450 1A2 substrateInhibitor0.5312
CYP450 2C9 inhibitorNon-inhibitor0.864
CYP450 2D6 inhibitorInhibitor0.5449
CYP450 2C19 inhibitorNon-inhibitor0.8177
CYP450 3A4 inhibitorNon-inhibitor0.5507
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6586
Ames testNon AMES toxic0.946
CarcinogenicityCarcinogens 0.6315
BiodegradationNot ready biodegradable0.9888
Rat acute toxicity3.5250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.947
hERG inhibition (predictor II)Inhibitor0.7606
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Vistapharm inc
  • Mallinckrodt chemical inc
  • Bioniche pharma usa llc
  • Sandoz inc
  • Mallinckrodt inc
  • The pharmanetwork llc
Packagers
Dosage forms
FormRouteStrength
LiquidOral10 mg
TabletOral1 mg
TabletOral10 mg
TabletOral25 mg
TabletOral5 mg
SolutionOral1 mg
Injection, solutionIntramuscular; Intravenous; Subcutaneous10 mg/mL
PowderOral1 g/g
SolutionOral10 mg/5mL
SolutionOral5 mg/5mL
TabletOral10 mg/1
ConcentrateOral10 mg/mL
SolutionOral10 mg
TabletOral5 mg/1
TabletOral40 mg/1
Prices
Unit descriptionCostUnit
Methadone hcl 10 mg/ml vial7.48USD ml
Methadone hcl powder5.91USD g
Metadol 25 mg Tablet1.69USD tablet
Metadol 10 mg Tablet0.9USD tablet
Methadone intensol 10 mg/ml0.85USD ml
Metadol 5 mg Tablet0.56USD tablet
Methadone hcl 10 mg tablet0.37USD tablet
Metadol Concentrate 10 mg/ml Liquid0.37USD ml
Methadone hcl 5 mg tablet0.34USD tablet
Dolophine hcl 10 mg tablet0.21USD tablet
Metadol 1 mg Tablet0.17USD tablet
Methadose 5 mg tablet0.16USD tablet
Methadose 10 mg tablet0.14USD tablet
Dolophine hcl 5 mg tablet0.13USD tablet
Metadol 1 mg/ml Solution0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point235.0 °CNot Available
logP3.93HANSCH,C ET AL. (1995)
pKa8.94 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility0.0059 mg/mLALOGPS
logP4.14ALOGPS
logP5.01ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)18.78ChemAxon
pKa (Strongest Basic)9.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.27 m3·mol-1ChemAxon
Polarizability36.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-9210000000-7542d8c3f742c7713c13View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Aralkylamine
  • Gamma-aminoketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G: Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002 Apr;19(4):459-60. [PubMed:11933204 ]
  4. Kakko J, von Wachenfeldt J, Svanborg KD, Lidstrom J, Barr CS, Heilig M: Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry. 2008 Jan 15;63(2):172-7. Epub 2007 Sep 11. [PubMed:17850768 ]
  5. Kvam TM, Baar C, Rakvag TT, Kaasa S, Krokan HE, Skorpen F: Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. J Mol Med (Berl). 2004 Apr;82(4):250-5. Epub 2004 Jan 9. [PubMed:14991152 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GE: Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res. 2009 Oct;60(4):284-90. doi: 10.1016/j.phrs.2009.04.002. Epub 2009 Apr 11. [PubMed:19717013 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor binding
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes t...
Gene Name:
CHRNA10
Uniprot ID:
Q9GZZ6
Molecular Weight:
49704.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Gross ER, Hsu AK, Gross GJ: Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg. 2009 Nov;109(5):1395-402. doi: 10.1213/ANE.0b013e3181b92201. [PubMed:19843777 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Deeb TZ, Sharp D, Hales TG: Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone. Mol Pharmacol. 2009 Apr;75(4):908-17. doi: 10.1124/mol.108.053322. Epub 2009 Jan 8. [PubMed:19131665 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. [PubMed:15371986 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. [PubMed:15371986 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Stormer E, Perloff MD, von Moltke LL, Greenblatt DJ: Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab Dispos. 2001 Jul;29(7):954-6. [PubMed:11408360 ]
  2. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4. [PubMed:19887017 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23